South Africa’s government has estimated that universities and science councils could lose about $107 million in U.S. research ...

Just before a major HIV vaccine trial was to begin, U.S. funding cuts halted South Africa’s BRILLIANT project, threatening ...

Just days before South African scientists were set to launch clinical trials of a promising HIV vaccine, their progress was ...

The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government says it has saved the lives of over 25 million people around the world ...

The withdrawal of U.S. funding under the Trump administration has halted key HIV vaccine trials in South Africa, part of a ...

South Africa will buy lenacapavir using Global Fund money. Studies show it can stop infections entirely in young women. But ...

The UNAIDS annual report warns that Trump-era HIV funding cuts could lead to 6 million more infections and 4 million deaths ...

Alarice Marsh, M.P.H., a deputy director in the National Department of Health of South Africa and program lead of HIV testing ...

At the University of the Witwatersrand, scientists are developing HIV vaccines that could help change the course of the ...

The results expose a striking prevalence of high-risk sexual behaviours. Over one-third of participants (34.0%) disclosed ...

A landmark breakthrough in HIV prevention received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effective that global health leaders had started ...